A meta-analysis of the relationship between lymphatic microvessel density and clinicopathological parameters in breast cancer

Bulletin du Cancer

Volumn 100, Issue 3, 2013, Pages

  Chen, Yigang ^a   Yan, Jun ^a   Yuan, Ziming ^a   Yu, Song ^a   Yang, Chengguang ^a   Wang, Zhigang ^a   Zheng, Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Breast cancer; Lymphatic microvessel density; Ymphangiogenesis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER SIZE; DISEASE ASSOCIATION; HEMATOLOGICAL PARAMETERS; HUMAN; LYMPH NODE METASTASIS; LYMPHATIC MICROVESSEL DENSITY; SYSTEMATIC REVIEW;

EID: 84876542683     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1719     Document Type: Article

References (108)

1. Gabriel EM, Jatoi I. Breast cancer chemoprevention. Expert Rev Anticancer Ther 2012; 12 : 223-8.
2. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-Analysis. Cancer Res 2004; 64 : 2941-55. (Pubitemid 38581387)
3. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio-And lymphangiogenesis. Br J Cancer 2007; 96 : 1092-100. (Pubitemid 46608319)
4. Thiele W, Sleeman JP. Tumor-induced lymphangiogenesis: a target for cancer therapy? J Biotechnol 2006; 124 : 224-41. (Pubitemid 43816134)
5. Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010; 17 : 229-51.
6. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004; 1654 : 3-12. (Pubitemid 38230927)
7. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2011; 31 : 4499-508.
8. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82 : 673-700. (Pubitemid 34743335)
9. Schoppmann SF, Birner P, Stockl J, et al. Tumor-Associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161 : 947-56. (Pubitemid 34988382)
10. Raica M, Cimpean AM, Ceausu R, Ribatti D. Lymphatic microvessel density, VEGF-C, and VEGFR-3 expression in different molecular types of breast cancer. Anticancer Res 2011; 31 : 1757-64.
11. Tsutsui S, Matsuyama A, Yamamoto M, et al. The Akt expression correlates with the VEGF-A and -C expression as well as the microvessel and lymphatic vessel density in breast cancer. Oncol Rep 2010; 23 : 621-30.
12. Sundlisaeter E, Dicko A, Sakariassen PO, Sondenaa K, Enger PO, Bjerkvig R. Lymphangiogenesis in colorectal cancer -prognostic and therapeutic aspects. Int J Cancer 2007; 121 : 1401-9. (Pubitemid 47328697)
13. Mohammed RA, Ellis IO, Mahmmod AM, et al. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol 2011; 24 : 774-85.
14. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001; 7 : 462-8. (Pubitemid 32707965)
15. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005; 18 : 105-10. (Pubitemid 40128102)
16. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005; 18 : 143-52. (Pubitemid 40128107)
17. Kato T, Prevo R, Steers G, et al. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer 2005; 93 : 1168-74. (Pubitemid 41670702)
18. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005; 91 : 125-32. (Pubitemid 40684925)
19. Mohammed RA, Ellis IO, Elsheikh S, Paish EC, Martin SG. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat 2009; 113 : 261-73.
20. Bono P,Wasenius VM, Heikkila P, Lundin J, Jackson DG, Joensuu H. High LYVE-1-ositive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res 2004; 10 : 7144-9. (Pubitemid 39487698)
21. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5 : 13.
22. Killeen PR. An alternative to null-hypothesis significance tests. Psychol Sci 2005; 16 : 345-53. (Pubitemid 40763678)
23. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-Analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
24. Vranic S, Frkovic-Grazio S, Bilalovic N, Gatalica Z. Angiogenesis in triple-negative adenoid cystic carcinomas of the breast. Virchows Arch 2011; 459 : 377-82.
25. Shibata MA, Iinuma M, Morimoto J, et al. Alpha-mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation. BMC Med 2011; 9 : 69.
26. Li C, Li R, Song H, et al. Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol 2011; 103 : 184-92.
27. Qin Li L, Huang HL, Ping JL, Xu W, Li J, Dai LC. Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. APMIS 2011; 119 : 103-10.
28. Tan JX,Wang XY, Li HY, et al.HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Int J Cancer 2011; 128 : 1303-15.
29. Kadota K, Huang CL, Liu D, et al. The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer. Lung Cancer 2010; 70 : 88-93.
30. Schoppmann SF, Tamandl D, Roberts L, et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-ositive breast cancer. Ann Oncol 2010; 21 : 955-60.
31. El-Gohary YM, Metwally G, Saad RS, Robinson MJ, Mesko T, Poppiti RJ. Significance of periductal lymphatic and blood vascular densities in intraductal carcinoma of the breast. Breast J 2009; 15 : 261-7.
32. El-Gendi S, Abdel-Hadi M. Lymphatic vessel density as prognostic factor in breast carcinoma: relation to clinicopathologic parameters. J Egypt Natl Canc Inst 2009; 21 : 139-49.
33. Karkkainen AM, Kotimaa A, Huusko J, et al. Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation. Blood 2009; 113 : 4468-75.
34. Xie XD, Qu SX, Zheng ZD, Song FL, Liu DW. Relation of lymphatic microvessel density detected by monoclonal antibody D2-40 with VEGF-C expression in breast cancer. Zhonghua Zhong Liu Za Zhi 2008; 30 : 356-60.
35. Xie XD, Qu SX, Liu ZZ, Zhang F, Zheng ZD. Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer. J Cancer Res Clin Oncol 2009; 135 : 413-9.
36. Popiela TJ, Sikora J, Klimek M, et al. The analysis of CD34 antigen immunoreactivity level in invasive ductal breast cancer with respect to the presence of lymph node metastases. Neuro Endocrinol Lett 2008; 29 : 443-6.
37. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68 : 2850-60. (Pubitemid 351556284)
38. Kadota K, Huang CL, Liu D, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 2008; 44 : 1057-67.
39. El-Gohary YM, Metwally G, Saad RS, Robinson MJ, Mesko T, Poppiti RJ. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas. Am J Clin Pathol 2008; 129 : 578-86. (Pubitemid 352029277)
40. Chen JS, Zhang YJ, Hu SE, Zhang HQ. Effects of VEGF-A/VEGF-C antisense oligodeoxynucleotide on angiogenesis, lymphangiogenesis, and tumor growth of breast cancer. Ai Zheng 2007; 26 : 972-6.
41. Mylona E, Nomikos A, Alexandrou P, Giannopoulou I, Keramopoulos A, Nakopoulou L. Lymphatic and blood vessel morphometry in invasive breast carcinomas: relation with proliferation and VEGF-C and -D proteins expression. Histol Histopathol 2007; 22 : 825-35. (Pubitemid 47034148)
42. Tezuka K, Onoda N, Takashima T, et al. Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients. Oncol Rep 2007; 17 : 997-1003.
43. Ou ZL,Wang J, Hou YF, Luo JM, Shen ZZ, Shao ZM. Downregulation of Duffy antigen receptor for chemokine (DARC) is associated with lymph node metastasis in human breast cancer. Zhonghua Zhong Liu Za Zhi 2006; 28 : 586-9.
44. Ivkovic-Kapicl T, Knelevic-Usaj S, Panjkovic M, Mastilovic K. Immunohistochemical analysis of angiogenesis in invasive ductal breast carcinoma with correlations to clinicopathological factor. Vojnosanit Pregl 2006; 63 : 635-42.
45. Schoppmann SF, Fenzl A, Nagy K, et al. VEGF-C expressing tumor-Associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006; 139 : 839-46. (Pubitemid 43902914)
46. Schoppmann SF, Fenzl A, Schindl M, et al. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 2006; 99 : 135-41. (Pubitemid 44268261)
47. Shibata MA, Ito Y, Morimoto J, Kusakabe K, Yoshinaka R, Otsuki Y. In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas. J Gene Med 2006; 8 : 335-52.
48. Hu SE, Zhang YJ, Cui YM, Zhang HQ. Expression of vascular endothelial growth factor A and C in human breast cancer and their significance. Ai Zheng 2005; 24 : 1076-9.
49. Chavez-Macgregor M, Aviles-Salas A, Green D, Fuentes-Alburo A, Gomez-Ruiz C, Aguayo A. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res 2005; 11 : 5396-400. (Pubitemid 41060813)
50. Longatto Filho A, Martins A, Costa SM, Schmitt FC. VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract 2005; 201 : 93-9. (Pubitemid 40443822)
51. Erdem O, Dursun A, Coskun U, Gunel N. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori 2005; 91 : 46-52. (Pubitemid 40469387)
52. Gong Y, Sun X, Huo L, Wiley EL, Rao MS. Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast. Histopathology 2005; 46 : 24-30. (Pubitemid 40193694)
53. Liu ZZ, Zhang HW, Wei B, Cui SD. Correlation of expression of heparanase to angiogenesis and prognosis of breast cancer. Ai Zheng 2004; 23 : 1342-5.
54. Watanabe O, Shimizu T, Imamura H, et al. IV-DSA is a new diagnostic tool for axillary lymph node metastasis in breast cancer patients. J Surg Oncol 2004; 87 : 75-9. (Pubitemid 39079652)
55. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004; 240 : 306-12. (Pubitemid 38963023)
56. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 2004; 57 : 746-51. (Pubitemid 38901491)
57. Rajesh L, Joshi K, Bhalla V, Dey P, Radotra BD, Nijhawan R. Correlation between VEGF expression and angiogenesis in breast carcinoma. Anal Quant Cytol Histol 2004; 26 : 105-8. (Pubitemid 38509042)
58. Jiang X, Huang X, Li J, Shi Y, Zhou L. Relationship between tissue inhibitors of metalloproteinase and metastasis and prognosis in breast cancer. Zhonghua Wai Ke Za Zhi 2000 ; 38 : 291-3 (219).
59. Olewniczak S, Chosia M, Kolodziej B, Kwas A, Kram A, Domagala W. Angiogenesis as determined by computerised image analysis and the risk of early relapse in women with invasive ductal breast carcinoma. Pol J Pathol 2003; 54 : 53-9. (Pubitemid 36604467)
60. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003; 200 : 195-206. (Pubitemid 36748028)
61. Liang YJ, Wu YZ, Gu MJ. Angiogenesis and micrometastases of regional lymph node in ovarian cancer. Ai Zheng 2003; 22 : 185-8.
62. Olewniczak S, Chosia M, Kwas A, Kram A, Domagala W. Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol 2002; 53 : 183-8. (Pubitemid 36193756)
63. McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002; 8 : 3857-62. (Pubitemid 35424780)
64. Lantzsch T, Hefler L, Krause U, et al. The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer. Anticancer Res 2002; 22 : 1925-8. (Pubitemid 34839222)
65. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002; 55 : 429-34. (Pubitemid 34620779)
66. Kalfon B, Fineberg S, Gu Y, et al. Microvessel density and p53 overexpression in young women with breast cancer: a case-control study. Clin Breast Cancer 2001; 2 : 67-72. (Pubitemid 32440427)
67. De Paola F, Granato AM, Scarpi E, et al. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 2002; 98 : 228-33. (Pubitemid 34150807)
68. Wu L, Zhang W, Liu H. Immunohistochemical study of angiogenesis of axillary lymph node metastasis in human breast carcinoma. Zhonghua Zhong Liu Za Zhi 1999; 21 : 433-5.
69. Toomey D, Smyth G, Condron C, et al. Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Cancer 2001; 92 : 2648-57. (Pubitemid 33049449)
70. Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S. Lymphatic microvessel density and lymphovascular invasion assessed by anti-odoplanin immunostaining in human breast cancer. Anticancer Res 2001; 21(4A) : 2351-5. (Pubitemid 33054395)
71. Wapnir IL, Barnard N, Wartenberg D, Greco RS. The inverse relationship between microvessel counts and tumor volume in breast cancer. Breast J 2001; 7 : 184-8. (Pubitemid 32619781)
72. Jiang X, Huang X, Li J. The correlation between tumor angiogenesis and lymph node metastasis in primary breast carcinoma. Zhonghua Wai Ke Za Zhi 1997; 35 : 583-5.
73. Guidi AJ, Berry DA, Broadwater G, et al. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 2000; 92 : 486-92. (Pubitemid 30182886)
74. Gonzalez-Vela MC, Garijo MF, Fernandez FA, Buelta L, Val-Bernal JF. Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. Pathol Res Pract 1999; 195 : 611-8. (Pubitemid 29431449)
75. Mortensen K, Holck S, Christensen IJ, et al. Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients. Clin Cancer Res 1999; 5 : 1093-7. (Pubitemid 29233224)
76. Dellas A, Torhorst J, Bachmann F, Banziger R, Schultheiss E, Burger MM. Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer 1998; 83 : 1376-83. (Pubitemid 28460089)
77. Gleich LL, Biddinger PW, Duperier FD, Gluckman JL. Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carcinoma: a clinical-Athologic correlation. Head Neck 1997; 19 : 276-80. (Pubitemid 27273105)
78. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997; 57 : 1259-63. (Pubitemid 27152548)
79. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-Term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996; 88 : 1764-9. (Pubitemid 26405014)
80. Ogawa Y, Chung YS, Nakata B, et al. Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer 1995; 71 : 1297-301.
81. Bevilacqua P, Barbareschi M, Verderio P, et al. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma -results of a multiparametric study. Breast Cancer Res Treat 1995; 36 : 205-17.
82. Gasparini G,Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12 : 454-66. (Pubitemid 24079885)
83. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas -relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 1994; 29 : 109-16. (Pubitemid 24104842)
84. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340 : 1120-4.
85. Axelsson K, Ljung BM, Moore 2nd. DH, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87 : 997-1008.
86. Zheng SQ, Huang RQ, Zhang YJ. Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer. Zhonghua Bing Li Xue Za Zhi 2010; 39 : 240-4.
87. Truong PT, Vinh-Hung V, Cserni G, Woodward WA, Tai P, Vlastos G. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-ositive breast cancer. Eur J Cancer 2008; 44 : 1670-7.
88. Raica M, Gaje PN, Ceausu AR, Cimpean AM. Clinical significance of lymphangiogenesis in molecular types of invasive breast cancer. EJC Suppl 2010; 8 : 1359-6349.
89. van den Eynden GG, van der Auwera I, van Laere SJ, et al. Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer. J Pathol 2007; 213 : 56-64. (Pubitemid 47354566)
90. Wu QW, She HQ, Liang J, et al. Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer.BMC Cancer 2012; 12 : 47.
91. van den Eynden GG, Vandenberghe MK, van Dam PJ, et al. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin Cancer Res 2007; 13(18 Pt 1) : 5391-7. (Pubitemid 47510365)
92. Gaje P, Cimpean AM, Raica M, Ribatti D. Lymphatic microvessel density and mast cells in molecular types of breast cancer. EJC Suppl 2010; 5 : 155-255.
93. Nathanson SD, Zarbo RJ,Wachna DL, Spence CA, Andrzejewski TA, Abrams J. Microvessels that predict axillary lymph node metastases in patients with breast cancer. Arch Surg 2000 ; 135 : 586-93 (discussion 593-584).
94. van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-Franse LV, Griffioen AW. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 2007; 254 : 128-36. (Pubitemid 47058811)
95. Kandemir NO, Barut F, Bektas S, Ozdamar SO. Can lymphatic vascular density be used in determining metastatic spreading potential of tumor in invasive ductal carcinomas? Pathol Oncol Res 2011.
96. Lee SK, Cho EY, Kim WW, et al. The prediction of lymph node metastasis in ductal carcinoma in situ with microinvasion by assessing lymphangiogenesis. J Surg Oncol 2010; 102 : 225-9.
97. Gu Y, Qi X, Guo S. Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases. Clin Exp Metastasis 2008; 25 : 717-25.
98. van Iterson V, Leidenius M, von Smitten K, Bono P, Heikkila P. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol 2007; 128 : 759-66. (Pubitemid 350133986)
99. Sheng W,Wang HX,Wang GH, Fan L, Tao S. VEGF-C expression and lymphangiogenesis in breast cancer. J Xipan Jiaotong Univ Med Sci 2008; 29 : 679-82.
100. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-Type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005; 166 : 913-21. (Pubitemid 40315647)
101. Da MX, Wu Z, Tian HW. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008; 39 : 365-72.
102. Sleeman J, Schmid A, Thiele W. Tumor lymphatics. Semin Cancer Biol 2009; 19 : 285-97.
103. Agarwal B, Saxena R, Morimiya A, Mehrotra S, Badve S. Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol 2005; 29 : 1449-55. (Pubitemid 41513294)
104. Ji RC. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: new insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 2006; 25 : 677-94.
105. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7 : 192-8. (Pubitemid 32148486)
106. Azizun N, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008; 9 : 553-6.
107. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323 : 42-6. (Pubitemid 32682008)
108. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-Analysis. Br J Cancer 2009; 100 : 1385-92.